IRWD Stock Overview
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Ironwood Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.11 |
| 52 Week High | US$15.70 |
| 52 Week Low | US$7.53 |
| Beta | 0.55 |
| 1 Month Change | 0.62% |
| 3 Month Change | -45.46% |
| 1 Year Change | -22.84% |
| 3 Year Change | -26.21% |
| 5 Year Change | -17.24% |
| Change since IPO | -30.39% |
Recent News & Updates
Recent updates
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Price Is Right But Growth Is Lacking After Shares Rocket 28%
Feb 16
Ironwood Pharmaceuticals: Capitalizing On GI Healthcare's Growing Potential
Jan 31Revenues Working Against Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price
Dec 19Ironwood Pharmaceuticals (NASDAQ:IRWD) Seems To Use Debt Rather Sparingly
Jul 25An Intrinsic Calculation For Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Suggests It's 39% Undervalued
Apr 18Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt
Mar 28Ironwood Pharmaceuticals: Rinse, Wash And Repeat
Oct 05These 4 Measures Indicate That Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Using Debt Safely
Sep 28Ironwood Pharma falls 7% as Linzess Q2 sales of drug from AbbVie weigh
Jul 29Ironwood Pharmaceuticals: Undervalued Company With Steady Growth
Sep 27Here's Why I Think Ironwood Pharmaceuticals (NASDAQ:IRWD) Might Deserve Your Attention Today
Jul 21Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt
Jun 22Shareholder Returns
| IRWD | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.9% | 3.4% | 1.6% |
| 1Y | -22.8% | 3.8% | 25.1% |
Return vs Industry: IRWD underperformed the US Biotechs industry which returned 2.8% over the past year.
Return vs Market: IRWD underperformed the US Market which returned 23.9% over the past year.
Price Volatility
| IRWD volatility | |
|---|---|
| IRWD Average Weekly Movement | 12.0% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IRWD's share price has been volatile over the past 3 months.
Volatility Over Time: IRWD's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 267 | Tom McCourt | www.ironwoodpharma.com |
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis.
Ironwood Pharmaceuticals, Inc. Fundamentals Summary
| IRWD fundamental statistics | |
|---|---|
| Market cap | US$1.29b |
| Earnings (TTM) | -US$1.00b |
| Revenue (TTM) | US$442.74m |
2.9x
P/S Ratio-1.3x
P/E RatioIs IRWD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IRWD income statement (TTM) | |
|---|---|
| Revenue | US$442.74m |
| Cost of Revenue | US$116.09m |
| Gross Profit | US$326.65m |
| Other Expenses | US$1.33b |
| Earnings | -US$1.00b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 09, 2024
| Earnings per share (EPS) | -6.31 |
| Gross Margin | 73.78% |
| Net Profit Margin | -226.37% |
| Debt/Equity Ratio | -201.5% |
How did IRWD perform over the long term?
See historical performance and comparison